Amerigo Scientific provides a diverse array of validated antibodies, with an unparalleled selection of blocking and neutralizing antibodies. Our dedication to quality ensures reliable results, empowering researchers to produce publication-grade data.
A neutralizing antibody safeguards cells against pathogens or infectious particles by neutralizing their biological activity. This process renders the particle non-infectious or non-pathogenic. Neutralizing antibodies are essential elements of the humoral response in the adaptive immune system, targeting intracellular bacteria, viruses, and microbial toxins. Through specific binding to surface antigens on infectious particles, neutralizing antibodies prevent these particles from interacting with host cells they may infect and subsequently eliminate them. A blocking antibody binds to its target and directly obstructs its function, such as inhibiting cell adhesion or receptor-ligand interactions. Conversely, a neutralizing antibody binds to its target and neutralizes downstream cellular effects, such as chemotaxis or cell proliferation.
Fig.1 Blocking and neutralizing antibodies in virus treatment.1, 2
Amerigo Scientific provides a diverse array of blocking and neutralizing antibodies spanning various research domains. These include but are not limited to immune checkpoint modulation, chemokine functionality, angiogenic regulators, and developmental factors.
Leverage our capabilities for conducting blocking and neutralizing bioassays. Our bioassay team will collaborate with you to develop and optimize a tailored assay. You will receive raw data along with a professionally formatted report that includes a comprehensive summary of the bioassay protocol utilized.
Flow Cytometry Antibodies | ELISA and Immunoassays Antibodies |
Immunofluorescence Antibodies | Immunohistochemistry Antibodies |
Immunoprecipitation Antibodies | Activating Antibodies |
Depletion Antibodies | Western Blot Antibodies |
Stimulatory Antibodies | Surface Plasmon Resonance Antibodies |
Amerigo Scientific has successfully produced a diverse array of neutralizing antibodies directed against well-established checkpoints. Additionally, we offer a comprehensive selection of blocking antibodies targeting prevalent surface antigens, encompassing not only common targets in hematological malignancies but also those in solid tumors. For more information, please feel free to
to explore how we can assist you in advancing your research objectives.References